Trial Profile
Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Tocilizumab SC as Monotherapy or in Combination With cDMARD Treatment in RA Patients in Greece: the EMBRACE-SC Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2019
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms EMBRACE-SC
- Sponsors Roche
- 21 Feb 2019 Status changed from active, no longer recruiting to completed.
- 24 Jul 2018 Planned End Date changed from 2 Sep 2018 to 30 Nov 2018.
- 24 Jul 2018 Planned primary completion date changed from 2 Sep 2018 to 30 Nov 2018.